Edition:
United Kingdom

Spectrum Pharmaceuticals Sells Marketed Portfolio To Acrotech Biopharma


Thursday, 17 Jan 2019 

Jan 17 (Reuters) - Spectrum Pharmaceuticals Inc ::SPECTRUM PHARMACEUTICALS SELLS MARKETED PORTFOLIO TO ACROTECH BIOPHARMA L.L.C. TO FOCUS ON NEW AND INNOVATIVE THERAPIES FOR CANCER PATIENTS.SPECTRUM PHARMACEUTICALS SELLS MARKETED PORTFOLIO TO ACROTECH BIOPHARMA L.L.C. TO FOCUS ON NEW AND INNOVATIVE THERAPIES FOR CANCER PATIENTS.SPECTRUM PHARMACEUTICALS INC - SPECTRUM WILL RECEIVE $160 MILLION IN AN UPFRONT CASH PAYMENT AND UP TO $140 MILLION IN REGULATORY AND SALES-BASED MILESTONES.SPECTRUM PHARMACEUTICALS INC - STAFF SIZE WILL BE REDUCED BY APPROXIMATELY 40 PERCENT WITH MAJORITY OF IMPACTED STAFF TRANSITIONING TO ACROTECH.SPECTRUM PHARMACEUTICALS - WILL RETAIN CORE GROUP OF COMMERCIAL TALENT TO LEAD LAUNCH OF ROLONTIS AND POZIOTINIB.SPECTRUM PHARMACEUTICALS - TO SELL ITS PORTFOLIO OF 7 FDA-APPROVED HEMATOLOGY/ONCOLOGY PRODUCTS TO ACROTECH BIOPHARMA LLC.